Botulinum Toxin A for Treatment of Allodynia of Complex Regional Pain Syndrome: A Pilot Study

Pain Medicine

Volumn 11, Issue 9, 2010, Pages 1411-1414

  Safarpour, D ^a   Salardini, Arash ^b   Richardson, Diana ^a,c   Jabbari, Bahman ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Allodynia; Botulinum toxin; Complex Regional Pain Syndrome (CRPS); Reflex Sympathetic Dystrophy (RSD)

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ALLODYNIA; ANALGESIA; ARTICLE; BRIEF PAIN INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX REGIONAL PAIN SYNDROME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MCGILL PAIN QUESTIONNAIRE; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PATIENT SATISFACTION; PILOT STUDY; POSTHERPETIC NEURALGIA; PROSPECTIVE PAYMENT; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 77956505368     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2010.00897.x     Document Type: Article

References (20)

1. Hou YP, Zhang YP, Song YF. Botulinum toxin type A inhibits rat pyloric myoelectrical activity and substance P release in vivo. Can J Physiol Pharmacol 2007, 85:209-14.
2. Lucioni A, Bales GT, Lotan TL. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int 2008, 101:366-70.
3. Cui M, Kanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004, 107:125-33.
4. Namazi H. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis: A molecular mechanism. Urology 2008, 72:463-4.
5. Filippi GM, Errico P, Santarelli R, Baqolini B, Manni E. Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400-4.
6. Bach-Rojecky L, Lackovic Z. Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Bihav 2009, 94:234-8.
7. Foster L, Clapp L, Erickson M, Jabbari B. Botulinum toxin A and chronic low back pain: A randomized, double-blind study. Neurology 2001, 56:1290-3.
8. Babcock MS, Foster L, Pasquina P, Jabbari B. Treatment of pain attributed to plantar fasciitis with botulinum toxin a: A short-term, randomized, placebocontrolled, double-blind study. Amer Rehab Med 2005, 84:649-54.
9. Heidi P, Theresa MS, Sheila AD. Recognizing and treating pelvic pain and pelvic floor dysfunction. Phys Med Rehabil Clin N Am 2007, 18:477-96.
10. Joel RS, Ninan TM, Elizabeth WL, Ronald D, Amanda MV. A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007, 8:478-85.
11. Gobel H, Heinze A, Reichel G, Hefter H, Benecke R. Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: Results from a randomized double-blind placebo-controlled multicenter study. Pain 2006, 125:82-8.
12. Ranoux D, Attal N, Morain F, Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol 2008, 64:274-84.
13. Harden N, Bruehl S, Stanton-Hicks M, Wilson P. Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med 2007, 8:326-31.
14. Luvisetto S, Marinelli S, Cobianchi S, Pavone F. Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience 2007, 145:1-4.
15. Park H, Lee Y, Lee J, Park C, Moon DE. The effect of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth 2006, 53:470-7.
16. Schulte-Mattler W, Opatz O, Blersch W. Botulinum toxin A does notalter capsaicin-induced pain perception in human skin. J Neurol Sci 2005, 260:38-42.
17. Kramer H, Angerer C, Erbguth F, Schmelz M, Birklein F. Botulinum toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 2003, 250:188-93.
18. Yuan RY, Sheu JJ, Yu JM. Botulinum toxin for diabetic neuropathic pain. Neurology 2009, 72:1473-8.
19. Carroll I, Clark D, Mackey S. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann Neurol 2009, 65:348-51.
20. Argoff CE. A focused review on the use of botulinum toxins for the neuropathic pain. Clin J Pain 2002, 18:177-81.